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plerixafor and G-CSF have similar immune reconstitution at
30 and 60 days post autologous transplantation compared to
patients mobilized with G-CSF alone.LATE EFFECTS/QUALITY OF LIFE/PSYCHOSOCIAL ISSUES
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Background: HCT is a lengthy, complex procedure with the
potential for decreased quality of life, transplant related
mortality, relapsed disease, and graft-versus-host disease.
Psychosocial assessments are a part of the overall HCT eval-
uation process, but there are very few validated psychosocial
instruments for this patient population. Recently, the SIPAT
has been shown to predict outcomes in solid organ trans-
plantation. A retrospective pilot study was performed on 25
consecutive HCT patients to investigate whether SIPAT re-
sults correlated with HCT outcomes.
Methods: The retrospective pilot study was modeled after
methodology published in any earlier SIPAT study conducted
by JR Maldonado (Psychosomatics, 2012). Two experienced
HCT reviewers, a physician and a social worker, and an
inexperienced reviewer, a transplant coordinator, conducted
the retrospective chart review, completing the SIPAT for 25
consecutive HCT recipients at the University of Virginia be-
tween January and October 2012. A clinical research coor-
dinator independently reviewed each patient’s medical
records and interviewed transplant coordinators to record
HCT recipient outcomes.
Results: HCT recipients (median age 52, 56% male) received
HCT’s for myeloma, lymphoma and leukemia. 14 recipients
received an allogeneic transplant, while 11 received an
autologous one. The inter-rater reliability between the
SIPAT reviewers was inconsistent. 2 reviewers correlated
well (R¼.84), while the other correlations between re-
viewers were weak (R¼.62 and R¼.55). It was noted that
there was a response shift in SIPAT reviewer 3 to lower
scores, indicating potential bias in reviewers 1 and 2 due to
prior patient exposure. To test possible associations of
psychosocial assessments with recipient outcomes, indi-
vidual reviewer SIPAT scores were plotted. These indicated
higher assessment scores were associated with poorer so-
cial support and compliance, and increased drug relapses,
and psychiatric symptoms. Other outcome measures such
as graft failure, treatment related mortality, re-hospitali-
zation and disease relapse failed to show a relationship
with SIPAT scores.
Conclusion: SIPAT scores may indicate positive relation-
ships between HCT psychosocial assessments and various
psychosocial outcomes. Due to the limited number of
transplant recipients in the retrospective review, it was
not possible to completely blind the experiencedreviewers. Bias may have been introduced resulting in
higher scores for these reviewers compared to the third
reviewer, who was new to the program. Additionally, the
poor inter-rater reliability of the SIPAT (in spite of educa-
tion and practice) may have arisen from the challenges of
scoring patients retrospectively through chart reviews, as
the program’s psychosocial assessment was not as detailed
as the SIPAT. These issues can be addressed in future
prospective studies.204
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Background: Through the use of an electronic medical re-
cord (EMR) based system, care managers, and single provider
physician oversight, we previously reported high concor-
dance rates of post hematopoietic stem cell transplant
(HSCT) screening based on ASBMT guidelines in a commu-
nity based, multi-facility care delivery system.
Objective: To demonstrate that case management in a
vertically integrated, EMR based community practice span-
ning 9 medical centers in a large metropolitan region can
consistently promote high concordance rates with published
ASBMT guidelines and lead to timely recognition of common
transplant associated complications.
Methods: Retrospective chart review of 74 consecutive pe-
diatric HSCT survivors (0-18yrs) from 2005-2013 looking for
concordance rates with 2012 ASBMT late effects guidelines.
The frequency of thyroid dysfunction, cataracts, pulmonary
disease, and ovarian dysfunction were noted as well as the
mean time to development. Majority of patients were treated
with fractionated TBI and therefore were at high risk of
developing late effects.
Results: We observed a sustained high level of concordance
(>90%) with screening guidelines in the period after a pop-
ulation care management approach was implemented
(2009-2013). This led to the timely identiﬁcation and man-
agement of HSCT associated complications.
Conclusion: An EMR based, vertically integrated health care
system facilitates effective community based post-HSCT
survivorship care in the pediatric population.205
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Background: Patients of stem cell transplantation (SCT) may
experience long-term symptoms that impact quality of life
and adjustment. Employment status has been identiﬁed as
an important marker for post-transplant adjustment.
p
KPS <0.0001
Walk velocity <0.0001
PBSC 0.0077
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S148Methods: The present study examined the association
between fatigue, pain, overall quality of life, and perceived
health status with employment at 1-year post-transplant.
Participants (N¼404) completed a lifestyle survey 1-year
post-SCT. Participants provided current employment sta-
tus and whether change was attributable to their health
status.
Results: Participants were predominatelymarried/partnered
(81.7%), Caucasian/Non-Hispanic (81.6%), males (52%) be-
tween ages 19-76 (mean: 56 years) and majority underwent
autologous transplants (70.1%). Prior to illness diagnosis,
60.8% were employed Full-Time, which decreased at the time
of transplant (35.5%) and at 1-year post-SCT (31.0%).
Employment status was correlated with all variables of in-
terest (p<0.05). Analysis of variance and chi-square analysis
were completed. Fatigue, pain, and quality of life were rated
on a 0-10 scale. Health status was rated as ‘excellent’ to ‘poor’
on a 5-point scale. Patients’ mean scores revealed low/
moderate fatigue (3.38), low pain (1.87) and good quality of
life (7.43). Most rated their health as ‘very good’ (26.9%) or
‘good’ (22.7%). Fatigue did not vary by employment status.
Pain was greatest for patients unemployed due to health
status compared to those employed full-time or unemployed
due to other (p<.05). Patients employed part-time enjoyed
greater quality of life than those unemployed due to Health
status (p<.05). Those employed full-time were most likely to
report ‘excellent’ (48.0%), ‘very good’ (37.5%), or ‘good’
(33.9%) health. ‘Fair’ health was mostly reported by those
unemployed due to health status (41.3%). Retirees, regardless
of health status, were most likely to report ‘poor’ health
(57.2%).
Conclusion: Patients’ ability and desire to return to work
post-transplant should be considered a meaningful compo-
nent of survivorship expectations and long-term adjustment.206
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Univariate analysis
Not fatigued
(N¼160)
Fatigued
(N¼103)
p
# prior cGVHD
therapies
3.5 4.2 0.007
PCS 39.3 29.9 <0.0001
MCS 50.4 42.4 <0.0001
ESR 22.6 28.8 0.007
CRP 6.1 7.7 0.019
TSH 1.8 2.2 0.035
HAP max activity score 74.7 65.4 <0.0001
HAP adj activity score 64.8 50.0 <0.0001
Nutrition score PG-
SGA
6.0 9.6 <0.0001Institute, NIH, Bethesda, MD; 5 Pain and Palliative Care,
National Cancer Institute, NIH, Besthesda, MD; 6 Pediatric
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Background: Chronic graft-versus-host disease (cGVHD) is a
major cause of morbidity and non-relapse mortality after
allogeneic hematopoietic cell transplantation (HCT).
Although fatigue is common after HCT, little is known about
fatigue in patients with cGVHD. The aim of this study was to
explore factors associated with fatigue in cGVHD.
Methods: Data were drawn from a cohort of adults with
cGVHD (n¼263). To classify patients as fatigued, a single item
(extent to which respondent was bothered in the past month
by loss of energy [LOE]) from the Lee cGVHD Symptom Scale
was employed. Those who were ‘not at all’, ‘slightly’, or
‘moderately’ bothered by LOE were classiﬁed as not fatigued;
those who were ‘quite a bit’ or ‘extremely’ bothered were
classiﬁed as fatigued. Nonparametric tests were used to
compare variables of interest in patients with and without
fatigue; logistic regression was used to model predictors of
fatigue.
Results: In univariate analysis, several parameters were
signiﬁcantly associated (p<0.005) or demonstrated a trend
towards signiﬁcant association (0.005p<0.05) with fatigue
(Table 1). Factors not associated were NIH global severity
score, NIH organ scores, # of involved organs, time since
cGVHD onset, platelets, hemoglobin, albumin, erythematous
or sclerotic skin involvement, intensity of immunosuppres-
sion, therapeutic intent at time of evaluation, age, gender,
BMI, conditioning regimen, donor source, C3, C4, pre-
albumin, ferritin, lung function score, FEV1, respiratory
symptoms, range of motion, and grip strength. Logistic
regression modeling initially including factors associated
with fatigue in univariate analysis demonstrated that having
received peripheral blood stem cells (PBSC) and having im-
pairments in self-rated physical and mental health predicted
fatigue. Fatigued respondents had SF36 physical component
score (PCS) and mental component score (MCS) means that
were markedly lower than US normative value, and human
activity proﬁle (HAP) scores reﬂecting limitation in daily
activities.
Conclusions: The absence of association with either NIH
cGVHD global severity or organ scores suggests that fatigue
in cGVHD patients may have a distinct pathogenesis. The
association with ESR and CRP point towards possible in-
ﬂammatory mediators. Findings conﬁrm the deleterious
impact of fatigue on self-rated health and daily activities, and
emphasize the need for routine screening in HCT survivors.
Further study of the characteristics, correlates, and conse-
quences of fatigue in cGVHD is warranted.207
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